Aspirin Resistance and Atherothrombotic Disease
Key result
Aspirin resistance affects up to ~45% of patients despite unclear mechanisms, diagnosis, and optimal therapy.
Why the study?
Despite aspirin's proven benefit in preventing atherothrombotic events, the absolute risk of recurrent vascular events remains high and aspirin resistance may contribute to this risk, yet many aspects of aspirin resistance remain unclear.
Authors
Discussion
Loading...
Member takes
Implication
Narrative review reveals potential aspirin resistance in patients with atherothrombotic disease, highlighting diagnostic uncertainties and persistent vascular risk.
Key Points
- To review the clinical impact, prevalence, and pathophysiological mechanisms of aspirin resistance in atherothrombotic disease.
- Narrative evaluation of clinical trials analyzing aspirin efficacy in the primary and secondary prevention of cardiovascular events.
- Literature synthesis examining proposed mechanisms, diagnostic limitations, and prevalence estimates of aspirin resistance.
- The absolute risk of recurrent vascular events in patients on aspirin remains relatively high, estimated at 8% to 18% after two years.
- Aspirin resistance may affect between 5% and 45% of the population, though validated measurement methods and formal diagnostic criteria are currently lacking.
- Definitive biological mechanisms, population-level prevalence, clinical significance, and targeted therapeutic strategies for overcoming resistance remain unestablished.
PICO
P
Population
Atherothrombotic disease
E
Exposure / Comparator
Aspirin resistance
Limitations
- Formal diagnostic criteria and a validated method of measurement are lacking
Cite This Study
Mason et al. (2005) conducted a review in Atherothrombotic disease. Aspirin resistance was evaluated. Aspirin resistance may affect between 5% and 45% of the population, but there are many unanswered questions regarding its biological mechanism, diagnosis, and optimal therapeutic intervention.